Gene therapy prolongs PSA doubling time in prostate cancer patients

Molecular Therapy

Volumn 15, Issue 3, 2007, Pages 442-443

  Thompson, Timothy C ^a   Rodriguez, Ron ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIANDROGEN; CYTOSINE DEAMINASE; FLUOROURACIL; GANCICLOVIR; PARVOVIRUS VECTOR; PROSTATE SPECIFIC ANTIGEN; THYMIDINE KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CLINICAL TRIAL; DRUG DOSE INCREASE; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; NOTE; PHENOTYPE; PROSTATE CANCER; RECURRENT CANCER; TRANSGENE; TUMOR IMMUNITY; VIRAL GENE THERAPY; VIRUS REPLICATION;

GENE THERAPY; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33847177322     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300085     Document Type: Note

References (12)

1. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L et al. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107-117.
2. Lupold, SE and Rodriguez, R (2005). Adenoviral gene therapy, radiation, and prostate cancer. Rev Urol 7: 193-202.
3. MacRae EJ, Giannoudis A, Ryan R, Brown NJ, Hamdy FC, Maitland N et al. (2006). Gene therapy for prostate cancer: Current strategies and new cell-based approaches. Prostate 66: 470-494.
4. Kaliberov, SA and Buchsbaum, DJ (2006). Gene delivery and gene therapy of prostate cancer. Expert Opin Drug Deliv 3: 37-51.
5. Freytag, SO, Rogulski, KR, Paielli, DL, Gilbert, JD and Kim, JH (1998). A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323-1333.
6. Rogulski, KR, Wing, MS, Paielli, DL, Gilbert JD, Kim, JH and Freytag, SO (2000). Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 11: 67-76.
7. Freytag, SO, Paielli, D, Wing, M, Rogulski, K, Brown, S, Kolozsvary, A, et al. (2002). Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 54: 873-885.
8. Freytag, SO, Stricker, H, Pegg, J, Paielli, D, Pradhan, DG, Peabody, J et al. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497-7506.
9. Freytag, SO, Khil, M, Stricker, H, Peabody, J, Menon, M, DePeralta-Venturina, M et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968-4976.
10. Freytag, SO, Strickler, H, Peabody, J, Pegg, J, Paielli, D, Movasas, B et al. (2007). Five-year follow up of clinical trial of replication-competent adenovirus-mediated suicide gene therapy for the treatment of locally recurrent prostate cancer: Effect of gene therapy on PSA doubling time. Mol Ther 15: 636-642.
11. Shaffer, DR and Scher, HI (2003). Prostate cancer: A dynamic illness with shifting targets. Lancet Oncol 4: 407-414.
12. Timme, TL, Fujita, N, Wang, HY, Naruishi, K, Kadmon, D, Amato, RJ, Miles, BJ, Ayala, G, Wheeler, TM, Teh, BS, Butler, EB and Thompson TC et al. (2006). Cytokine Gene Therapy for Genitourinary Cancer. Humana Press: Totowa, NJ.